Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Avigan-Administered French Ebola Patient Recovers
October 7, 2014
- AnGes MG Commences Patient Registration in US for Collategene PIII Study
October 7, 2014
- Januvia Remains No. 1, Trazenta Climbs to No. 2 in GP Market in Anterio’s “Mind Share” Ranking for August
October 6, 2014
- JCR Pharmaceuticals Hopes to Make Japan’s First Cell Product into New Profit Pillar
October 6, 2014
- Takeda Directors Face 3-Month Pay Cut over CASE-J Issue
October 6, 2014
- Daiichi Sankyo Opens Representative Office in Vietnam
October 6, 2014
- Takeda to Invest in Alfresa Corporation’s Vaccine-Related Subsidiary
October 6, 2014
- Eisai Launches Halaven in Australia
October 3, 2014
- Santen Completes Transfer of Ophthalmology Assets from Merck
October 3, 2014
- Jim Murphy, GM of Alcon US Vision Care, Leads Alcon Japan as New President
October 3, 2014
- MTPC Charges Ahead with Research Lab Overhaul to Buttress Drug Discovery
October 2, 2014
- Daiichi Sankyo Seeks Tuberculosis Indication for Cravit, AGs
October 2, 2014
- MTPC Paid 19.8 Billion Yen to Physicians, Medical Institutions in FY2013
October 2, 2014
- Novartis Pharma Notifies PMDA of Additional 1,299 Unreported Serious ADRs
October 2, 2014
- AZ Starts J-DISCOVER Observational Study of Type 2 Diabetes Management
October 2, 2014
- Sumitomo Dainippon Obtains Patent License from Dnavec for Production of Clinical iPS Cells
October 2, 2014
- Kissei to Spice Up Current Portfolio in Next 3 Years, Launch New Drugs Later
October 1, 2014
- Takeda, MacroGenics Sign Second Agreement to Develop Autoimmune Disease Treatments
October 1, 2014
- Sumitomo Dainippon’s FY2013 Payments to Healthcare Professionals at 13.1 Billion Yen
October 1, 2014
- Kyowa Kirin, Pfizer to Collaborate on Cancer Immunotherapy
October 1, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…